Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilematovir Phase 2a in RSV
NCT03379675Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 2 trial of rilematovir in respiratory syncytial virus infection (RSV), sponsored by Janssen Pharmaceutical. Started Feb 2018; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03379675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03379675.